LCP
EW icon

Legacy Capital Partners’s Edwards Lifesciences EW Stock Holding History

Legacy Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-7,800
Closed -$244K – 111
2016
Q4 		$244K Sell
7,800
-1,200
-13% -$38.9K 0.15% 102
2016
Q3 		$362K Buy
9,000
+300
+3% +$11.3K 0.23% 90
2016
Q2 		$290K Buy
+8,700
New +$298K 0.18% 98

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legacy Capital Partners's EW Position: Q1 2017 in Review

Legacy Capital Partners sold out of Edwards Lifesciences (EW) in Q1 2017, closing a stake of 7,800 shares — an estimated $244K sold.

Legacy Capital Partners first reported a position in EW in Q2 2016 and held it in 3 quarters. The position peaked at $362K in Q3 2016. 690 funds tracked by Wall St. Rank hold EW as of Q1 2017.

  • Legacy Capital Partners reported no remaining Edwards Lifesciences position as of Q1 2017 after selling out during the quarter.
  • Legacy Capital Partners sold 7,800 Edwards Lifesciences shares in Q1 2017, an estimated $244K.
  • Legacy Capital Partners first reported a position in Edwards Lifesciences in Q2 2016 and held it in 3 quarters.
  • Legacy Capital Partners's Edwards Lifesciences position peaked at $362K in Q3 2016.
  • 690 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2017.

Based on Legacy Capital Partners's 13F filing for Q1 2017, filed 9 May 2017.